🇺🇸 FDA
Pipeline program

BOTULINUM TOXIN , -

BTXclintrialv1

Phase 2 small_molecule active

Quick answer

BOTULINUM TOXIN , - for Myogenous temporomandibular disorders (TMDM) is a Phase 2 program (small_molecule) at Institut für biomedizinische Analytik NMR-Imaging GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Institut für biomedizinische Analytik NMR-Imaging GmbH
Indication
Myogenous temporomandibular disorders (TMDM)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials